PKMYT1 and neoplasm: With respect to additional genetic alterations that could benefit from PKMYT1 inhibition, tumours with mutations in FBXW7 (which encodes a substrate adaptor for the E3 ligase that targets cyclin E for ubiquitin-dependent proteolysis44) represents a target, given that cyclin E drives genome instability in these tumours45.